These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 8247532)

  • 1. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage.
    Aloni-Grinstein R; Zan-Bar I; Alboum I; Goldfinger N; Rotter V
    Oncogene; 1993 Dec; 8(12):3297-305. PubMed ID: 8247532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.
    Shaulsky G; Goldfinger N; Rotter V
    Cancer Res; 1991 Oct; 51(19):5232-7. PubMed ID: 1717142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1.
    Gulati AP; Yang YM; Harter D; Mukhopadhyay A; Aggarwal BB; Benzil DL; Whysner J; Albino AP; Murali R; Jhanwar-Uniyal M
    Mol Carcinog; 2006 Jan; 45(1):26-37. PubMed ID: 16267831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild-type murine p53 represses transcription from the murine c-myc promoter in a human glial cell line.
    Moberg KH; Tyndall WA; Hall DJ
    J Cell Biochem; 1992 Jun; 49(2):208-15. PubMed ID: 1400626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-Methylcholanthrene inactivates the p53 gene in Syrian hamster embryo fibroblasts by inducing a specific intronic point mutation.
    Albor A; Flessate DM; Soussi T; Notario V
    Cancer Res; 1994 Aug; 54(16):4502-7. PubMed ID: 8044802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of p53 transactivation through high-affinity binding sites.
    Chumakov AM; Miller CW; Chen DL; Koeffler HP
    Oncogene; 1993 Nov; 8(11):3005-11. PubMed ID: 8414502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53.
    Zastawny RL; Salvino R; Chen J; Benchimol S; Ling V
    Oncogene; 1993 Jun; 8(6):1529-35. PubMed ID: 8502478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does wild-type p53 play a role in normal cell differentiation?
    Rotter V; Aloni-Grinstein R; Schwartz D; Elkind NB; Simons A; Wolkowicz R; Lavigne M; Beserman P; Kapon A; Goldfinger N
    Semin Cancer Biol; 1994 Jun; 5(3):229-36. PubMed ID: 7948951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of prostate specific antigen (PSA) is negatively regulated by p53.
    Gurova KV; Roklin OW; Krivokrysenko VI; Chumakov PM; Cohen MB; Feinstein E; Gudkov AV
    Oncogene; 2002 Jan; 21(1):153-7. PubMed ID: 11791186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 promotes selection for Fas-mediated apoptotic resistance.
    Maecker HL; Koumenis C; Giaccia AJ
    Cancer Res; 2000 Aug; 60(16):4638-44. PubMed ID: 10969818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents.
    Grombacher T; Eichhorn U; Kaina B
    Oncogene; 1998 Aug; 17(7):845-51. PubMed ID: 9780001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of genes whose expressions are altered in rat 6 fibroblasts transformed by mutant p53(val135).
    Yam JW; Zheng JY; Hsiao WL
    Biochem Biophys Res Commun; 1999 Dec; 266(2):472-80. PubMed ID: 10600527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proliferation-associated early response gene p22/PRG1 is a novel p53 target gene.
    Schäfer H; Trauzold A; Sebens T; Deppert W; Fölsch UR; Schmidt WE
    Oncogene; 1998 May; 16(19):2479-87. PubMed ID: 9627114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional regulation of the Ig kappa gene by promoter-proximal pausing of RNA polymerase II.
    Raschke EE; Albert T; Eick D
    J Immunol; 1999 Oct; 163(8):4375-82. PubMed ID: 10510378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines.
    Mukhopadhyay T; Roth JA
    Anticancer Res; 1996; 16(1):105-12. PubMed ID: 8615594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular cloning and functional analysis of the promoter region of rat nonmuscle myosin heavy chain-B gene.
    Yam JW; Chan KW; Li N; Hsiao WL
    Biochem Biophys Res Commun; 2000 Oct; 276(3):1203-9. PubMed ID: 11027611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
    Liang Y; Wu J; Stancel GM; Hyder SM
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.
    Sun SY; Yue P; Hong WK; Lotan R
    Cancer Res; 2000 Nov; 60(22):6537-43. PubMed ID: 11103825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of the tumor suppressor gene p53 in tumor necrosis factor-induced differentiation of the leukemic cell line K562.
    Ehinger M; Nilsson E; Persson AM; Olsson I; Gullberg U
    Cell Growth Differ; 1995 Jan; 6(1):9-17. PubMed ID: 7718488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.